Loading clinical trials...

Performance of the Travoprost Intraocular Implant | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Performance of the Travoprost Intraocular Implant

Prospective, Non-Randomized, Open-Label, Single Center Study to Evaluate the Performance of the Travoprost Intraocular Implant

NCT06582732•Glaukos Corporation

View on ClinicalTrials.gov

Summary

To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid at specified timepoints post administration through 24 months

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of either open angle glaucoma (i.e. primary, pseudoexfoliation, or pigmentary glaucoma) or ocular hypertenson
•Zero to three topical intraocular pressure lowering medications at the time of Visit 1 (Screening) exam.
•Best spectacle corrected visual acuity of 16 letters or more correctly read at 4 meters or better in each eye.
•Open angle as defined by Shaffer grade ≥ 3 at slit-lamp at the planned implantation site

Exclusion Criteria

•Traumatic, uveitic, neovascular, or angle-closure glaucoma; or glaucoma associated with vascular disorders
•Active ocular inflammation, infection or edema
•Clinically significant dystrophy (e.g., bullous keratopathy, Fuch's dystrophy) or clinically significant guttata

Locations (1)

Glaukos Clinical Study Site

Yerevan, Armenia

Key Dates

Start Date

March 10, 2021

Primary Completion Date

November 2, 2023

Completion Date

November 2, 2023

Last Updated

October 15, 2024

Enrollment

210

ACTUAL participants

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

Travoprost Intracameral Implant exchanged at Month 12

DRUG

Travoprost Intracameral Implant exchanged at Month 3

DRUG

Travoprost Intracameral Implant exchanged at Month 6

DRUG

Travoprost Intracameral Implant exchanged at Month 24

DRUG

Travoprost intracameral implant exchanged at Month 21

DRUG

Travoprost intracameral implant exchanged at Month 18

DRUG

Travoprost intracameral implant exchanged at Month 15

DRUG

DSLT for Reducing Medication in Glaucoma

NCT07390890

Primary Open Angle GlaucomaOcular Hypertension

View study

RECRUITINGNA

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

NCT05902871

Primary Open Angle GlaucomaOcular Hypertension+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Performance of the Travoprost Intraocular Implant

Inclusion Criteria

Exclusion Criteria

DSLT for Reducing Medication in Glaucoma

Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population

Feasibility Clinical Evaluation of the Calibreye System

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT